The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Whole genome sequencing of circulating tumor cells in multiple myeloma
Shaji Kumar, MD, Mayo Clinic, Rochester, MN, discusses the development of whole genome sequencing of circulating tumor cells as a potential approach for identifying genomic alterations associated with immunotherapy response and resistance in multiple myeloma. He highlights the potential to use peripheral blood to assess abnormalities such as TP53 and BCMA mutations while reducing reliance on repeated bone marrow biopsies, and discusses the validation, regulatory and clinical considerations needed for broader implementation. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
